| Kylee J Roller, PHD | |
|
16771 15th St Ne, Buxton, ND 58218-9239 | |
| (701) 792-6488 | |
| (701) 335-7100 |
| Full Name | Kylee J Roller |
|---|---|
| Gender | Female |
| Speciality | Psychologist |
| Location | 16771 15th St Ne, Buxton, North Dakota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750415873 | NPI | - | NPPES |
| 054519 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | (* (Not Available)) | Primary |
| Entity Name | Lipp Carlson Witucki & Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043316961 PECOS PAC ID: 2062408701 Enrollment ID: O20040420001654 |
News Archive
Ferrer, a privately-held Spanish pharmaceutical company, today announces that the first patient has been recruited into a second phase III trial of Ozenoxacin, formulated as a topical treatment for infectious dermatological conditions in adult and paediatric patients with impetigo. The study is scheduled to complete in Q1, 2015.
Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration.
Hospitalar—Welch Allyn, a leading global manufacturer of frontline medical products and solutions, is reconfirming its commitment to caregivers in Latin America with innovative solutions to healthcare issues that are unique to the region. In March 2009 the company acquired MD International (MDI), now Welch Allyn Latin America, and has since gained significant market share in South and Central America, Mexico and the Caribbean thanks to strong relationships with large distribution and manufacturer partners.
The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, has received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System for the treatment of drug resistant Major Depressive Disorder (MDD) in the United States. The clearance enables Magstim to significantly increase access to cutting-edge Repetitive Transcranial Magnetic Stimulation (rTMS) technology for patients and clinicians.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kylee J Roller, PHD 16771 15th St Ne, Buxton, ND 58218-9239 Ph: (701) 792-6488 | Kylee J Roller, PHD 16771 15th St Ne, Buxton, ND 58218-9239 Ph: (701) 792-6488 |
News Archive
Ferrer, a privately-held Spanish pharmaceutical company, today announces that the first patient has been recruited into a second phase III trial of Ozenoxacin, formulated as a topical treatment for infectious dermatological conditions in adult and paediatric patients with impetigo. The study is scheduled to complete in Q1, 2015.
Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration.
Hospitalar—Welch Allyn, a leading global manufacturer of frontline medical products and solutions, is reconfirming its commitment to caregivers in Latin America with innovative solutions to healthcare issues that are unique to the region. In March 2009 the company acquired MD International (MDI), now Welch Allyn Latin America, and has since gained significant market share in South and Central America, Mexico and the Caribbean thanks to strong relationships with large distribution and manufacturer partners.
The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, has received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System for the treatment of drug resistant Major Depressive Disorder (MDD) in the United States. The clearance enables Magstim to significantly increase access to cutting-edge Repetitive Transcranial Magnetic Stimulation (rTMS) technology for patients and clinicians.
› Verified 9 days ago